Aardvark Therapeutics paused two Phase II trials of its oral weight‑loss candidate ARD‑201 while conducting a comprehensive data review; the decision follows a voluntary pause earlier in the company’s ARD‑101 program after cardiac observations. Aardvark said it is engaging the FDA urgently to determine next steps and emphasized patient safety. The pause removes the company’s near‑term clinical catalysts and has halted its broader pipeline, which drove heavy share volatility after prior safety‑related disclosures.